Allelic loss at 19q12 and Xq11-12 predict an adverse clinical outcome in patients with mucinous ovarian tumours of low malignant potential

British Journal of Cancer

Volumn 90, Issue 6, 2004, Pages 1204-1210

  Nakayama, K ^a   Takebayashi, Y ^b   Hata, K ^a   Fujiwaki, R ^a   Iida, K ^a   Fukumoto, M ^c   Miyazaki, K ^a  

^a SHIMANE UNIVERSITY   (Japan)

^b Giju University School of Medicine   (Japan)

^c TOHOKU UNIVERSITY   (Japan)

Author keywords

Loss of heterozygosity; Mucinous LMP; Ovarian carcinoma; Prognosis

Indexed keywords

KI 67 ANTIGEN;

ADULT; ALLELE; APOPTOSIS; ARTICLE; CANCER RISK; CANCER SURVIVAL; CHROMOSOME 19Q; CHROMOSOME XQ; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GENETIC MARKER; GENOME; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; MUCINOUS CARCINOMA; OUTCOMES RESEARCH; OVARY CARCINOMA; PREDICTION; PRIORITY JOURNAL; REGRESSION ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE;

ADENOCARCINOMA, MUCINOUS; ADULT; CHROMOSOMES, HUMAN, PAIR 19; CHROMOSOMES, HUMAN, X; DISEASE-FREE SURVIVAL; FEMALE; GENETIC MARKERS; HUMANS; LOSS OF HETEROZYGOSITY; MICROSATELLITE REPEATS; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 1942501699     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601681     Document Type: Article

References (44)

1. Beder LB, Gunduz M, Ouchida M, Fukushima K, Gunduz E, Ito S, Sakai A, Nagai N, Nishizaki K, Shimizu K (2003) Genome-wide analyses on loss of heterozygosity in head and neck squamous cell carcinomas. Lab Invest 83: 99-105
2. Callahan R, Campbell G (1989) Mutations in human breast cancer: an overview. J Natl Cancer Inst 81: 1780-1786
3. Casey AC, Bell DA, Lage JM, Fuller AF, Nikrui N, Rice LW (1993) Epithelial ovarian tumors of borderline malignancy, long-term follow-up. Gynecol Oncol 50: 316-322
4. Choi SW, Choi JR, Chung YJ, Kim KM, Rhyu MG (2000) Prognostic implications of microsatellite genotypes in gastric carcinoma. Int J Cancer 89: 378-383
5. Choi SW, Lee KJ, Bae YA, Min KO, Kwon MS, Kim KM, Rhyu MG (2002) Genetic classification of colorectal cancer based on chromosomal loss and microsatellite instability predicts survival. Clin Cancer Res 8: 2311-2322
6. Cuatrecasas M, Matias-Guiu X, Prat J (1996) Synchronous mucinous tumors of the appendix and the ovary associated with Pseudomyxoma peritonei. A clinicopathologic study of six cases with comparative analysis of c-Ki-ras mutations. Am J Surg Pathol 20: 739-746
7. Edelson MI, Lau CC, Colitti CV, Welch WR, Bell DA, Berkowitz RS, Mok SC (1998) A one centimorgan deletion unit on chromosome Xq12 is commonly lost in borderline and invasive epithelial ovarian tumors. Oncogene 16: 197-202
8. FIGO (1987) Changes in definitions of clinical staging for carcinoma of the cervix and ovary: International Federation of Gynecology and Obstetrics. Am J Obstet Gynecol 156: 263-264
9. Gershenson DM (1999) Contemporary treatment of borderline ovarian tumors. Cancer Invest 17: 206-210
10. Guerrieri C, Franlund B, Boeryd B (1995) Expression of cytokeratin 7 in simultaneous mucinous tumors of the ovary and appendix. Mod Pathol 8: 573-576
11. Guerrieri C, Franlund B, Fristedt S, Gillooley JF, Boeryd B (1997) Mucinous tumors of the vermiform appendix and ovary, and Pseudomyxoma peritonei: histogenetic implications of cytokeratin 7 expression. Hum Pathol 28: 1039-1045
12. Hata K, Yoshida M, Maruyama R, Fujiwaki R, Miyazaki K (2002) Prognostic significance of ultrasound derived intratumoral peak systolic velocity in epithelial ovarian cancer. Ultrasound Obstet Gynecol 20: 186-191
13. Hirano A, Emi M, Tsuneizumi M, Utada Y, Yoshimoto M, Kasumi F, Akiyama F, Sakamoto G, Haga S, Kajiwara T, Nakamura Y (2001) Allelic losses of loci at 3p25.1, 8p22, 13q12, 17p13.3, and 22q13 correlate with postoperative recurrence in breast cancer. Clin Cancer Res 7: 876-882
14. Hu J, Pang JC, Tong CY, Lau B, Yin XL, Poon WS, Jiang CC, Zhou LF, Ng HK (2002) High-resolution genome-wide allelotype analysis identifies loss of chromosome 14q as a recurrent genetic alteration in astrocytic tumours. Br J Cancer 87: 218-224
15. Huettner PC, Weinberg DS, Lage JM (1992) Assessment of proliferative activity in ovarian neoplasms by flow and static cytometry. Correlation with prognostic features. Am J Pathol 141: 699-706
16. Kaern J, Trope C, Kjorstad KE, Abeler V, Pettersen EO (1990) Cellular DNA content as a new prognostic tool in patients with borderline tumors of the ovary. Gynecol Oncol 38: 452-457
17. Knudson AG (1993) Antioncogenes and human cancer. Proc Natl Acad Sci USA 90: 10914-10921
18. Link Jr CJ, Reed E, Sarosy G, Kohn EC (1996) Borderline ovarian tumors. Am J Med 101: 217-225
19. Lee KR, Scully RE (2000) Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with 'Pseudomyxoma peritonei'. Am J Surg Pathol 24: 1447-1464
20. Mandai M, Konishi I, Kuroda H, Komatsu T, Yamamoto S, Nanbu K, Matsushita K, Fukumoto M, Yamabe H, Mori T (1998) Heterogeneous distribution of K-ras-mutated epithelia in mucinous ovarian tumors with special reference to histopathology. Hum Pathol 29: 34-40
21. Nakashima N, Nagasaka T, Oiwa N, Nara Y, Fukata S, Fukatsu T, Takeuchi J (1990) Ovarian epithelial tumors of borderline malignancy in Japan. Gynecol Oncol 38: 90-98
22. Nakayama K, Kanzaki A, Hata K, Katabuchi H, Okamura H, Miyazaki K, Fukumoto M, Takebayashi Y (2002) Hypoxia-inducible factor 1 alpha (HIF-1 alpha) gene expression in human ovarian carcinoma. Cancer Lett 176: 215-223
23. Nakayama K, Takebayashi Y, Nakayama S, Hata K, Fujiwaki R, Fukumoto M, Miyazaki K (2003a) Prognostic value of overexpression of p53 in human ovarian carcinoma patients receiving cisplatin. Cancer Lett 192: 227-235
24. Nakayama K, Takebayashi Y, Namiki T, Tamahashi N, Nakayama S, Uchida T, Miyazaki K, Fukumoto M (2001) Comprehensive allelotype study of ovarian tumors of low malignant potential: potential differences in pathways between tumors with and without genetic predisposition to invasive carcinoma. Int J Cancer 94: 605-609
25. Nakayama S, Nakayama K, Takebayashi Y, Hata K, Fujiwaki R, Fukumoto M, Miyazaki K (2003b) Allelotypes as potential prognostic markers in ovarian carcinoma treated with cisplatin-based chemotherapy. Int J Mol Med 11: 621-625
26. Nunn J, Scholes AG, Liloglou T, Nagini S, Jones AS, Vaughan ED, Gosney JR, Rogers S, Fear S, Field JK (1999) Fractional allele loss indicates distinct genetic populations in the development of squamous cell carcinoma of the head and neck (SCCHN). Carcinogenesis 20: 2219-2228
27. Padberg BC, Lauritzen I, Achilles E, Holl K, Bressel M, Kloppel G, Dralle H, Schroder S (1991) DNA cytophotometry in adrenocortical tumours: a clinicomorphological study of 66 cases. Virchows Arch 419: 167-170
28. Pecorelli S, Fallo L (1998) Hormone replacement therapy in gynecological cancer survivors. Crit Rev Oncol Hematol 27: 1-10
29. Prayson RA, Hart WR, Petras RE (1994) Pseudomyxoma peritonei. A clinicopathologic study of 19 cases with emphasis on site of origin and nature of associated ovarian tumors. Am J Surg Pathol 18: 591-603
30. Rosin MP, Lam WL, Poh C, Le ND, Li RJ, Zeng T, Priddy R, Zhang L (2002) 3p14 and 9p21 loss is a simple tool for predicting second oral malignancy at previously treated oral cancer sites. Cancer Res 62: 6447-6450
31. Russel NH, Hunter AE, Haynes A, Bessell EM (1994) Multiple myeloma. BMJ 308: 1715
32. Schwartz DR, Kardia SL, Shedden KA, Kuick R, Michailidis G, Taylor JM, Misek DE, Wu R, Zhai Y, Darrah DM, Reed H, Ellenson LH, Giordano TJ, Fearon ER, Hanash SM, Cho KR (2002) Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 62: 4722-4729
33. Seidman JD, Elsayed AM, Sobin LH, Tavassoli FA (1993) Association of mucinous tumors of the ovary and appendix. A clinicopathologic study of 25 cases. Am J Surg Pathol 17: 22-34
34. Serov SF, Scully RE, Sobin LH (1973) Histopathological Typing of Ovarian Tumors. International Classification of Tumors, Vol. 9. Geneva: WHO
35. Shi SR, Key ME, Kalra KL (1991) Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 39: 741-748
36. Siriaunkgul S, Robbins KM, McGowan L, Silverberg SG (1995) Ovarian mucinous tumors of low malignant potential: a clinicopathologic study of 54 tumors of intestinal and Mullerian type. Int J Gynecol Pathol 14: 198-208
37. Szych C, Staebler A, Connolly DC, Wu R, Cho KR, Ronnett BM (1999) Molecular genetic evidence supporting the clonality and appendiceal origin of Pseudomyxoma peritonei in women. Am J Pathol 154: 1849-1855
38. Tamakoshi K, Kikkawa F, Nakashima N, Tamakoshi A, Kawai M, Furuhashi Y, Hattori SE, Kuzuya K, Arii Y, Suganuma N, Tomoda Y (1997) Clinical behavior of borderline ovarian tumors: a study of 150 cases. J Surg Oncol 64: 147-152
39. Taylor HC (1929) Malignant and semimalignant tumors of the ovary. Surg Obstet Gynecol 48: 204-230
40. Tazelaar HD, Bostwick DG, Ballon SC, Hendrickson MR, Kempson RL (1985) Conservative treatment of borderline ovarian tumors. Obstet Gynecol 66: 417-422
41. Trimble CL, Trimble EL (1994) Management of epithelial ovarian tumors of low malignant potential. Gynecol Oncol 55: S52-61
42. Wingo PA, Tong T, Bolden S (1995) Cancer statistics, 1995. CA Cancer J Clin 45: 8-30
43. Winter III WE, Kucera PR, Rodgers W, McBroom JW, Olsen C, Maxwell GL (2002) Surgical staging in patients with ovarian tumors of low malignant potential. Obstet Gynecol 100: 671-676
44. Young RH, Gilks CB, Scully RE (1991) Mucinous tumors of the appendix associated with mucinous tumors of the ovary and Pseudomyxoma peritonei. A clinicopathological analysis of 22 cases supporting an origin in the appendix. Am J Surg Pathol 15: 415-429